RxDoctor Payments Data

Kim Hinojosa

Family · San Antonio, TXNPI 1366754715

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $39,089 of the $62,966 with a category attached, or 62.1%. 4 manufacturers reported payments, led by Gilead at 58.2% of the total. Reporting peaked in 2022 at $20,403 and has fallen 66.6% since, to $6,811 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,966in general payments, 2019–2025

Across 127 payments — averaging $495.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$37K
  • AbbVie$26K
  • E.r. Squibb & Sons, L.L.C.$121
  • Boston Scientific$14

What the payments were for

  • Consulting fees$4,0806%
  • Speaking & faculty fees$39,08962%
  • Travel & lodging$16,24826%
  • Food & beverage$3,5506%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead61$36,636
AbbVie64$26,196
E.r. Squibb & Sons, L.L.C.1$121
Boston Scientific1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,966 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$21,376
Medicare patients
106
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin130$403,625
Skyrizi PenRisankizumab-Rzaa11$217,129
VemlidyTenofovir Alafenamide75$109,545
OzempicSemaglutide26$53,420
MounjaroTirzepatide18$20,382
EliquisApixaban15$17,383
Omeprazole24$611
Olmesartan Medoxomil16$567
Atorvastatin Calcium44$444
Albuterol Sulfate HfaAlbuterol Sulfate16$356
Cefdinir25$353
Ciprofloxacin Hcl42$326
Vitamin D2Ergocalciferol (Vitamin D2)42$306
Gabapentin20$298
Telmisartan16$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$36,636$109,54575 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →